Spectral AI, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Spectral AI, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.65M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $29.58M | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | $18.06M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $25.37M | Mar 29, 2024 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.93M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $13.27M | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | $7.88M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $10.84M | Mar 29, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.57M) | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | ($15.16M) | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | ($20.85M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($2.91M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($2.15M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($675) | Mar 31, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($8.60M) | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | ($6.58M) | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | ($12.98M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($2.65M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($3.42M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($675) | Mar 31, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $15.10M | Mar 29, 2024 |
| FY2023 | Dec 31, 2022 | $16.50M | Mar 29, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($9.92M) | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | ($9.20M) | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | ($13.24M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($1.16M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($825.6K) | Mar 31, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $21.41M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $12.10M | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | $10.69M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $18.72M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $254.11M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $164.9K | Mar 31, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $27.13M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $19.35M | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | $12.40M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $6.72M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $21.93M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $140.6K | Mar 31, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.73M) | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | ($7.25M) | Mar 25, 2026 |
| FY2025 | Dec 31, 2023 | ($2.15M) | Mar 25, 2026 |
| FY2024 | Dec 31, 2022 | $12.00M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $13.75M | Mar 29, 2024 |
| FY2022 | Dec 31, 2020 | $24.3K | Mar 31, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($55.80M) | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | ($48.23M) | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | ($32.79M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($11.93M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($20.83M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($675) | Mar 31, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.40M | Mar 25, 2026 |
| FY2024 | Dec 31, 2024 | $5.20M | Mar 31, 2025 |
| FY2023 | Dec 31, 2023 | $4.79M | Mar 29, 2024 |
| FY2023 | Dec 31, 2022 | $14.17M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $769.4K | Mar 31, 2023 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.25M | Mar 25, 2026 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 29, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 29, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 30.69M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | 22.59M | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | 16.29M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 13.17M | Mar 29, 2024 |